Rising pregabalin use and misuse in Australia: trends in utilization and intentional poisonings.

Background and aims: Pregabalin is a gamma‐aminobutyric acid (GABA) analogue, used to treat neuropathic pain and epilepsy. Pregabalin was registered in Australia in 2005, and subsidized publically in 2013. We aimed to describe Australian patterns of pregabalin use and intentional poisoning, and iden...

Descripción completa

Detalles Bibliográficos
Publicado en:Addiction Vol. 114; no. 6; pp. 1026 - 1035
Autores principales: Cairns, Rose, Schaffer, Andrea L., Ryan, Nicole, Pearson, Sallie‐Anne, Buckley, Nicholas A.
Formato: research tables/charts Journal Article
Publicado: Wiley-Blackwell Jun2019
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=136380952&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 136380952
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        09652140
        AIO
      jtl: Addiction
      issn: 09652140
      maglogo: Y
    pubinfo:
      dt: Jun2019
      vid: 114
      iid: 6
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        136380952
        136380952
        136380952
        10.1111/add.14412
        136380952
      ppf: 1026
      ppct: 9
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: C
          – @attributes:
              type: P
      tig:
        atl: Rising pregabalin use and misuse in Australia: trends in utilization and intentional poisonings.
      aug:
        au:
          Cairns, Rose
          Schaffer, Andrea L.
          Ryan, Nicole
          Pearson, Sallie‐Anne
          Buckley, Nicholas A.
        affil: New South Wales Poisons Information Centre, The Children's Hospital at Westmead, Westmead NSW, Australia
      sug:
        subj:
          Pregabalin Poisoning
          Substance Abuse Risk Factors
          Substance Abuse Trends
          Human
          Australia
          Retrospective Design
          Prospective Studies
          Toxicology
          Wales
          Substance Abuse Mortality
          Persons with Substance Use Disorders
          Structural Equation Modeling
          Confidence Intervals
          Drugs, Prescription
          Narcotics
          Antianxiety Agents, Benzodiazepine
          Street Drugs
          Mental Disorders
          Comorbidity
          Male
          Sex Factors
          Age Factors
          Male
      ab: Background and aims: Pregabalin is a gamma‐aminobutyric acid (GABA) analogue, used to treat neuropathic pain and epilepsy. Pregabalin was registered in Australia in 2005, and subsidized publically in 2013. We aimed to describe Australian patterns of pregabalin use and intentional poisoning, and identify people potentially at high risk of misuse. Design and setting Population‐based retrospective cohort study of dispensings in the 10% sample of Australian Pharmaceutical Benefits Scheme (July 2012–February 2017); intentional poisoning calls to New South Wales Poisons Information Centre (NSWPIC) (2004–2016); intentional poisonings in two Australian toxicology service databases; and poisoning fatalities in NSW coronial records (2005–2016). Participants: A total of 122 572 people dispensed pregabalin, people with intentional pregabalin overdoses managed by NSWPIC and the toxicology services and pregabalin‐associated deaths referred to the NSW coroner. Measurements Trends in dispensing, poisoning, death; demographics and patient characteristics, proportion of users at high risk of misuse (latent class analysis, LCA) and characteristics of high‐risk users. Findings Pregabalin dispensing increased by 73 424 per year [95% confidence interval (CI) = 61726–85 121 P < 0.001] between 2013 and 2016. NSWPIC received 1158 reports of intentional pregabalin poisonings, with a 53.8% increase per year, 2005–2016 (95% CI = 44.0–64.2%, P < 0.001). We identified 88 pregabalin‐associated deaths, 57.8% yearly increase (95% CI = 30.0–91.6%, P < 0.001). Patients overdosing on pregabalin commonly co‐ingested opioids, benzodiazepines and illicit drugs, and had high rates of psychiatric and substance use comorbidities; 14.7% of pregabalin users were classed by the LCA as at high risk of misuse, and were more likely to be younger, male, co‐prescribed benzodiazepines or opioids, have more individual prescribers and higher pregabalin strengths dispensed. Conclusions: There has been a dramatic increase in pregabalin use, poisonings and deaths in Australia since it became subsidized publicly in 2013. One in seven Australians dispensed pregabalin appears to be at high risk of misuse.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N